BridgeBio Pharma, Inc.

Bayer’s pharmaceuticals unit enjoyed a surprisingly strong quarter at the start of 2025 but CEO Bill Anderson has said he would not be upping full-year forecasts for the division, given the “present g

BridgeBio Pharma’s Attruby (acoramidis) delivered $36.7m in sales during the first quarter of 2025 – three times analyst consensus of $12m for the transthyretin amyloidosis with cardiomyopathy (ATTR-C

A single-arm study cannot provide interpretable results supporting promotional claims for progression-free survival or overall survival, the US Food and Drug Administration said in an advertising and

Alnylam Pharmaceuticals’ Amvuttra (vitrisiran) will tap a substantially larger commercial opportunity with its US Food and Drug Administration approval for the treatment of ATTR with cardiomyopathy, b